◈ Nootpedia
Compact view
Research pass: medium Compound NOT-RELEVANT MEDIUM

Osteogenic Growth Peptide (OGP)

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict NOT-RELEVANT MEDIUM

Interesting bench-science peptide for bone formation + hematopoiesis but human clinical data is essentially zero. Dylan has no bone deficit, no marrow suppression, no fracture. Would change only if a small clinical trial showed safety + efficacy AND Dylan had a bone indication.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    NOT-RELEVANT

    No bone deficit. No cognitive benefit claimed.

  • 30-50, executive maintenance
    NOT-RELEVANT

    unless DEXA shows osteopenia, in which case use proven agents (vitamin D, weight-bearing exercise, possibly bisphosphonate / teriparatide / abaloparatide).

  • 50+, mild cognitive decline
    NOT-RELEVANT

    for cognition. For osteoporosis, use proven Rx options (teriparatide, abaloparatide, romosozumab, denosumab, bisphosphonates).

  • Anxiety-prone
    NOT-RELEVANT
  • High athletic load, tested status
    NOT-RELEVANT

    for primary use; might be peripherally interesting for stress-fracture recovery but data is too thin to recommend.

  • Sleep-disordered
    NOT-RELEVANT
  • Recovery-focused (post-injury, post-illness)
    WATCH-LIST LOW

    If a documented stress fracture or post-chemotherapy marrow recovery context — discuss with medical team. Otherwise BPC-157 / TB-500 / proper nutrition + load management have better evidence base.

  • Strength/anabolic-focused
    NOT-RELEVANT

    No muscle-tissue effect demonstrated.

▸ Subjective experience (deep)

Per scattered forum reports: minimal to no acute subjective effect. Some report mild well-being / "recovery" feel during use, hard to distinguish from placebo or co-administered peptides (BPC-157, TB-500).

▸ Tolerance + cycling deep dive
  • No tolerance data
  • Anecdotal cycles 4-6 weeks on / off — no scientific basis
▸ Stacking deep dive

Synergistic with

  • In bench/animal studies: G-CSF (hematopoietic synergy), BMPs (additive osteogenic)
  • Forum-claimed (low evidence): BPC-157, TB-500 for "complete recovery stack" — no rigorous data

Avoid stacking with

  • Active malignancy (theoretical mitogenic concern)
  • Other osteoanabolic drugs (teriparatide, abaloparatide) — no data on combination

Neutral / safe co-administration

  • Cannot make safe-stacking claims given absent human data
▸ Drug interactions deep dive

None characterized in humans. Peptide cleared by proteolysis — no CYP interactions.

▸ Pharmacogenomics

None known.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem Various peptide vendors (Pepsciences, Limitless Life when available, etc.) $40-100 per 10 mg vial medium "Research only" labeling; COA quality variable
Compounding pharmacy Rare; some specialized US pharmacies make OGP(10-14) for orthopedic specialists varies medium-high Not a routine offering

For Dylan: Don't source — no use case.

▸ Biomarkers to track (deep)
  • Baseline (if ever using): P1NP, CTX, ALP, vitamin D, calcium, CBC
  • During use: P1NP/CTX every 6-12 weeks; CBC monitoring given hematopoietic effects
  • Post-cycle: Same panel + DEXA at 6-12 months if bone outcome desired
▸ Controversies / open debates Live debate
  • Receptor identity still unresolved — biology of action depends on a Gi-coupled receptor that has not been cloned, weakening the mechanistic story.
  • Translational gap: 35+ years of preclinical work without a single registered clinical trial is a red flag — suggests pharma evaluators saw obstacles (delivery, stability, IP, or efficacy that didn't translate).
  • Forum confusion: Often conflated with PTH analogs (teriparatide, abaloparatide) or mistakenly classified alongside healing peptides like BPC-157. OGP is mechanistically distinct from both.
  • Stability problem: Native 14-aa OGP has very short serum half-life. OGP(10-14) is more stable but still requires frequent dosing or modified analogs that don't have safety data.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT MEDIUM. Documented because user dump put it on the queue alongside BMP-2 — same "interesting bone biology" cluster, similarly inappropriate for Dylan's profile and significantly less clinically validated than BMP-2.
▸ Open questions / gaps Open
  • Any phase-1 human safety trial — there isn't one published. Until that exists, off-label biohacker use is essentially uncharted.
  • Whether OGP(10-14) provides additive benefit over BPC-157 + TB-500 in soft-tissue/bone recovery context — no head-to-head data.
▸ Sources (full, with our context)
Back to compact view